Compare UXIN & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UXIN | CRBP |
|---|---|---|
| Founded | 2011 | 2009 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 226.6M | 190.3M |
| IPO Year | 2018 | 2014 |
| Metric | UXIN | CRBP |
|---|---|---|
| Price | $0.88 | $3.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $35.89 |
| AVG Volume (30 Days) | 170.4K | ★ 808.1K |
| Earning Date | 09-24-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,822,272.00 |
| Revenue This Year | $59.68 | N/A |
| Revenue Next Year | $71.25 | $116.00 |
| P/E Ratio | $4.05 | ★ N/A |
| Revenue Growth | N/A | ★ 97.62 |
| 52 Week Low | $0.82 | $3.93 |
| 52 Week High | $4.18 | $18.11 |
| Indicator | UXIN | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 32.02 | 18.15 |
| Support Level | N/A | N/A |
| Resistance Level | $1.27 | $9.66 |
| Average True Range (ATR) | 0.08 | 0.38 |
| MACD | -0.03 | 0.03 |
| Stochastic Oscillator | 15.76 | 5.70 |
Uxin Ltd is an investment holding company. Along with its subsidiaries, the firm operates a car retailer, pioneering industry transformation with production, new retail experiences, and digital empowerment in China. With its inventory-owning model, it provides customers a comprehensive transaction solution that encompasses the entire value chain, ranging from used-car acquisition, inspection, and reconditioning, warehousing, as well as pre-sales and after-sales services. The group offers high-quality and value-for-money used cars as well as superior full suites of services to customers through a reliable, one-stop, and hassle-free transaction experience. It derives revenues from retail vehicle sales, wholesale vehicle sales, and other businesses. The Group generates its revenues in China.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.